Stock earnings page

NanoViricides, Inc. (NNVC)

Track the next or latest earnings date for NanoViricides, Inc., review consensus estimates, and see cached AI analysis for recent quarterly results.

View this earnings week Open in the app

Recent earnings news

NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola
stocktwits.com · 1 day ago

Shares of NanoViricides (NNVC) jumped nearly 10% on Monday after the biotech firm announced progress toward a Phase II clinical trial of its experimental antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.

NanoViricides advances NV-387 Ebola trial in DRC | NNVC Stock News
www.stocktitan.net · 1 day ago

DRC has 1,561 confirmed Ebola cases and 506 deaths as NanoViricides prepares submissions for ethics and regulatory approval to start Phase II.

Buy NanoViricides Stock – NNVC Stock Quote Today & Investment Insights - Public.com
public.com · Recent

Looking to buy NanoViricides Stock? Get the latest NNVC quote, news, earnings, forecast, price targets, and market insights. Start investing on Public.com.

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC - InvestorWire (IW)
investorwire.com · 1 day ago

NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic ...

Why NN (NNBR) Stock Is Trading Lower Today
finance.yahoo.com · 5 days ago

Shares of industrial components supplier NN (NASDAQ:NNBR) fell 13.9% in the afternoon session after the company announced it raised $75 million through a private placement of common stock.

Latest earnings date

Feb 13, 2026

Time not specified

Fiscal quarter: Dec/2025

EPS estimate: -$0.14

Revenue estimate: N/A

Market cap: $20.06M

Analysis snapshot

No cached AI earnings analysis is available for this stock yet. Check back after the company reports or open the app to generate a fresh analysis.

Recent earnings history

Browse the calendar week

Date	Quarter	Report window	EPS est.	Revenue est.
Feb 13, 2026	Dec/2025	Time not specified	-$0.14	N/A